Lista de obras -

A new circulating recombinant form, CRF15_01B, reinforces the linkage between IDU and heterosexual epidemics in Thailand

artículo científico publicado en 2003

A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection

artículo científico publicado en 2017

A novel strategy to adapt SHIV-E1 carrying env from an RV144 volunteer to rhesus macaques: coreceptor switch and final recovery of a pathogenic virus with exclusive R5 tropism.

artículo científico publicado en 2018

Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand

artículo científico publicado en 2015

Aggregate complexes of HIV-1 induced by multimeric antibodies

artículo científico publicado en 2014

Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial

artículo científico publicado en 2014

Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial

artículo científico publicado en 2013

Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved

artículo científico publicado en 2014

Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women

artículo científico publicado en 2017

Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family

artículo científico publicado en 2012

Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion

artículo científico publicado en 2012

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.

artículo científico publicado en 2017

Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency

artículo científico publicado en 2020

CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.

artículo científico publicado en 2014

COMPASS identifies T-cell subsets correlated with clinical outcomes

artículo científico publicado en 2015

Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens

artículo científico publicado en 2016

Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial

artículo científico publicado en 2015

Correction: Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection

artículo científico publicado en 2017

Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection.

artículo científico publicado en 2018

Expansion of Inefficient HIV-Specific CD8 T Cells during Acute Infection

artículo científico publicado en 2016

Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.

artículo científico publicado en 2012

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial

artículo científico publicado en 2014

Factors influencing estimates of HIV-1 infection timing using BEAST

artículo científico publicado en 2021

HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions

scientific article published on 30 January 2020

HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders

artículo científico publicado en 2015

HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities

artículo científico publicado en 2014

HIV-specific antibody-dependent phagocytosis matures during HIV infection.

artículo científico publicado en 2014

HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial

artículo científico publicado en 2014

HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition

scientific article published on July 2015

Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques

artículo científico publicado en 2015

Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor

artículo científico publicado en 2015

Identification of immunodominant CD4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B/E.

artículo científico publicado en 2015

IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens

artículo científico publicado en 2015

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

artículo científico publicado en 2012

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

artículo científico publicado en 2012

Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses

artículo científico publicado en 2014

Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees

artículo científico publicado en 2013

Machine learning methods enable predictive modeling of antibody feature:function relationships in RV144 vaccinees

artículo científico publicado en 2015

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials

artículo científico publicado en 2012

Molecular dating and viral load growth rates suggested that the eclipse phase lasted about a week in HIV-1 infected adults in East Africa and Thailand

artículo científico publicado en 2020

Molecular epidemiology of HIV Type 1 in preparation for a Phase III prime-boost vaccine trial in Thailand and a new approach to HIV Type 1 genotyping

scientific article published on 01 August 2006

Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial

artículo científico publicado en 2013

Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial

artículo científico publicado en 2013

Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines

artículo científico publicado en 2014

Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand

artículo científico publicado en 2016

RV144 HIV-1 vaccination impacts post-infection antibody responses

artículo científico publicado en 2020

Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial

artículo científico publicado en 2017

Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection

artículo científico publicado en 2017

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

artículo científico publicado en 2012

Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee

artículo científico publicado en 2015

Temporal Dynamics of CD8+ T Cell Effector Responses during Primary HIV Infection

artículo científico publicado en 2016

The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

artículo científico publicado en 2012

The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope

artículo científico publicado en 2012

Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques

artículo científico publicado en 2016

V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.

artículo científico publicado en 2017

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

artículo científico publicado en 2013

Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination

artículo científico publicado en 2014

Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide

artículo científico publicado en 2014

Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses

artículo científico publicado en 2014

Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection

artículo científico publicado en 2014

Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG.

artículo científico publicado en 2013

Lista de obras de

A new circulating recombinant form, CRF15_01B, reinforces the linkage between IDU and heterosexual epidemics in Thailand

A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection

A novel strategy to adapt SHIV-E1 carrying env from an RV144 volunteer to rhesus macaques: coreceptor switch and final recovery of a pathogenic virus with exclusive R5 tropism.

Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand

Aggregate complexes of HIV-1 induced by multimeric antibodies

Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial

Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial

Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved

Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women

Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family

Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.

Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency

CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.

COMPASS identifies T-cell subsets correlated with clinical outcomes

Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens

Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial

Correction: Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection

Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection.

Expansion of Inefficient HIV-Specific CD8 T Cells during Acute Infection

Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial

Factors influencing estimates of HIV-1 infection timing using BEAST

HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions

HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders

HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities

HIV-specific antibody-dependent phagocytosis matures during HIV infection.

HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial

HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition

Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques

Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor

Identification of immunodominant CD4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B/E.

IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses

Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees

Machine learning methods enable predictive modeling of antibody feature:function relationships in RV144 vaccinees

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials

Molecular dating and viral load growth rates suggested that the eclipse phase lasted about a week in HIV-1 infected adults in East Africa and Thailand

Molecular epidemiology of HIV Type 1 in preparation for a Phase III prime-boost vaccine trial in Thailand and a new approach to HIV Type 1 genotyping

Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial

Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial

Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines

Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand

RV144 HIV-1 vaccination impacts post-infection antibody responses

Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial

Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee

Temporal Dynamics of CD8+ T Cell Effector Responses during Primary HIV Infection

The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope

Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques

V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination

Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide

Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses

Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection

Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG.